RedHill Biopharma (RDHL) Free Cash Flow (2016 - 2022)
Historic Free Cash Flow for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to -$2.4 million.
- RedHill Biopharma's Free Cash Flow rose 8370.36% to -$2.4 million in Q4 2022 from the same period last year, while for Dec 2023 it was -$2.4 million, marking a year-over-year increase of 9164.8%. This contributed to the annual value of -$9.4 million for FY2024, which is 7386.13% up from last year.
- As of Q4 2022, RedHill Biopharma's Free Cash Flow stood at -$2.4 million, which was up 8370.36% from -$6.0 million recorded in Q3 2022.
- Over the past 5 years, RedHill Biopharma's Free Cash Flow peaked at -$2.4 million during Q4 2022, and registered a low of -$19.0 million during Q3 2021.
- For the 5-year period, RedHill Biopharma's Free Cash Flow averaged around -$10.8 million, with its median value being -$9.9 million (2018).
- In the last 5 years, RedHill Biopharma's Free Cash Flow tumbled by 11103.83% in 2021 and then soared by 8370.36% in 2022.
- Over the past 5 years, RedHill Biopharma's Free Cash Flow (Quarter) stood at -$8.2 million in 2018, then tumbled by 68.96% to -$13.8 million in 2019, then increased by 8.53% to -$12.7 million in 2020, then fell by 17.38% to -$14.9 million in 2021, then skyrocketed by 83.7% to -$2.4 million in 2022.
- Its Free Cash Flow was -$2.4 million in Q4 2022, compared to -$6.0 million in Q3 2022 and -$16.4 million in Q2 2022.